Olema Pharmaceuticals, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Olema is a clinical-stage biopharmaceutical company developing targeted therapies for women’s cancers. It has no approved products and has generated no product revenue.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $19.5m | $17.6m | $60.3m | $60.7m |
| General and administrative expense | $3.9m | $5.6m | $14.3m | $19.1m |
| Total operating expenses | $23.3m | $23.2m | $74.5m | $79.8m |
| Net loss | $21.5m | $22.7m | $69.9m | $78.6m |
| Net loss per share, basic and diluted | $0.48 | $0.57 | $1.66 | $1.97 |
| Operating cash flow | Not provided for quarter | Not provided for quarter | $(65.3)m | $(62.4)m |
- At September 30, cash and cash equivalents were $117.4m and marketable securities were $159.5m, totaling $276.9m. Current assets were $282.0m and current liabilities $16.0m, or approximately $266.0m of working capital.
- Olema reported no debt outstanding. A secured credit facility provides $25.0m available following the private placement; another $25.0m is subject to bank approval. The facility matures August 2027 and bears interest at the higher of 8% or prime if drawn.
- Gross margin is not applicable because the company has no product sales. No operating cash flow was reported for the three-month period.
Changes versus comparable periods
- Q3 net loss narrowed by $1.2m year over year, despite R&D expense increasing $1.8m as clinical operations advanced. Lower G&A expense, down $1.7m, and higher interest income contributed to the improvement.
- Nine-month net loss narrowed by $8.7m. Operating expenses fell $5.2m, mainly from lower G&A and reduced preclinical and personnel costs; increased clinical spending partly offset the R&D reductions. Higher interest income also supported the improved result.
- Nine-month operating cash use increased by $2.9m year over year. Financing cash inflow rose to $132.9m, primarily reflecting the September private placement, versus $0.2m in the prior-year period.
- The September private placement issued 13.2m shares at $9.84 per share for approximately $130.0m gross and $129.8m net proceeds. Shares outstanding rose to 54.6m from 40.3m at December 31, 2022.
Outlook, commentary and risks
- Management expects cash, cash equivalents, marketable securities and the available credit facility to fund its current operating plan into 2027. It forecast cash, cash equivalents and marketable securities of $250m–$255m at December 31, 2023.
- The company expected to enroll the first patient in its proposed Phase 3 palazestrant monotherapy trial, OPERA-01, in Q4 2023. It also expected to report updated combination-trial results in December 2023 and plans to file an IND for its KAT6 program in 2024.
- Management expects significant losses to continue and expenses to increase as palazestrant development progresses. The runway estimate depends on assumptions; further funding may be needed, and financing could dilute shareholders or constrain operations.
- Palazestrant is the company’s lead candidate and remains in clinical development. Trial outcomes, regulatory review, enrollment, manufacturing and competition create material execution risks. The reported monotherapy results were clinical data, not evidence of approval or commercial success.
- The filing states the financial statements assume continued operations but also says accumulated losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern over the long term. Management’s stated runway into 2027 is based on its current operating plan.
- Other risks include reliance on third-party manufacturers and trial providers, potential clinical and regulatory delays, intellectual-property challenges, and geopolitical or macroeconomic disruption. The filing reports no pending material litigation and no material change in disclosure controls; management concluded those controls were effective at a reasonable assurance level.
Important facts for investors to verify
- Whether OPERA-01 began enrollment on the planned timeline and how its design, recruitment and costs compare with the operating plan.
- Updated efficacy and safety data for palazestrant monotherapy and combination studies, including whether preliminary findings hold as data mature.
- The assumptions supporting the cash runway into 2027, expected cash balance at year-end 2023, and pace of operating cash use.
- Availability and terms of the additional $25m credit tranche, and the costs and covenants of drawing the secured facility.
- The effects of the private placement and potential future equity or debt financing on dilution, liquidity and existing shareholders.